Redx reaches pre-clinical proof of concept with Oncology lead

11 May 2015

Drug discovery and development company Redx Pharma has reached pre-clinical proof of concept stage with an advanced lead which has the potential to tackle some of the most hard-to-treat cancers including pancreatic, breast and head and neck cancer.

The novel, potent small molecule Porcupine inhibitor targets the Wnt pathway, an embryonic signalling pathway that is implicated in the maintenance of cancer stem cells in multiple cancer types. These are associated with tumorigenesis, metastasis, recurrence and resistance in cancer. It will have the potential to be taken orally by patients as a once daily dose.

The lead has advanced through Redx’s innovative development pipeline to pre-clinical proof of concept in just over 12 months. Only one other similar treatment exists, this is currently in clinical development.

Dr Neil Murray, CEO of Redx Pharma, said: We’re very pleased to have reached preclinical proof of concept with this very promising program. The cancers it has the potential to tackle are some of the most notoriously hard-to-treat out there, so we’re delighted to be making steps on the journey to address this challenge and to have developed this novel Porcupine inhibitor which will help to tackle these areas of high unmet need.

Redx Pharma’s access to primary patient sample and extensive niche expertise in cancer stem cell assays, have proved particularly helpful in this instance. This program is a perfect demonstration of Redx’s capabilities – taking a program to proof of concept in just over 12 months from a standing start. We look forward to continuing to develop our Porcupine assets and assess their potential as a treatment for pancreatic, triple negative breast, and head and neck cancers.

Redx is focused on the development of proprietary, small molecule therapeutics to address areas of high unmet medical need, principally in cancer and infection. By improving the characteristics of existing drug classes to create highly differentiated, novel, best in class drugs. Redx has already established a portfolio of 13 proprietary drug programs. Five programs have achieved pre-clinical proof of concept, with relevance for respective therapies to treat MRSA, solid tumours, and blood cancers.


For more information about Redx Pharma’s drug development pipeline, click here.